Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Trial Profile

Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2021.
    • 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2016 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top